Skip to main content
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc.

Track LCTX — free
$0.77 -0.05 (-5.87%) At close · Nov 20
Market Cap
$195.26M
Shares
252.95M
Volume · Nov 20 2.04M Avg daily vol (3M) 1.63M

Price & Indicators

 

Key stats

Close
$0.77
Fri 20 Nov
Open
$0.81
Fri 20 Nov
Average volume, 30 days
2.0M
shares a session
Short interest
24.3M
9.6% of shares · 19.3 days to cover
Day range
$0.77$0.84
Open $0.81 Close $0.77
52-week closing range
$0.77$1.96
Close $0.77 60.6% under the high
Short volume, last session
43%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 12
Earnings call
Acquires HUNT-1 program for Huntington’s disease

Lineage acquired NeuroAIRMID, adding the clinical-stage HUNT-1 neural stem cell program for Huntington’s disease. Its 21-patient Phase 1B2A trial is enrolling, while $45.2 million in cash and marketable securities is expected to fund operations into the second quarter of 2028.

5 source passages
our acquisition of NeuroAIRMID and the HUNT1 neuronal cell therapy. we announced that we had acquired NeuroAirmid Therapeutics, a private biotech company founded on technology licensed from the lab of world-leading Huntington's disease researcher, Dr. Leslie Thompson. Lineage also offered something even more important and useful to the future of this product candidate. with a 21-patient Phase 1B2A trial currently enrolling. As of September 30, 2026, we had $45.2 million in cash, cash equivalents, and marketable securities, which we expect will fund planned operations into the second quarter of 2028. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Acquires NeuroAirmid to advance HUNT1 for Huntington’s Disease

Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones.

Revenue $1.43M ▼ 61.0% Net income $4.23M Diluted EPS -$0.03
Read from the MD&A section
3 source passages
On November 12, 2026, we acquired NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), by acquiring all of the outstanding common stock of NeuroAirmid from its stockholders (the “Sellers”). In connection with the acquisition, NeuroAirmid entered into an Amended and Restated Exclusive License Agreement, effective November 12, 2026 (the “License Agreement”), with The Regents of the University of California (“The Regents”), related to a pluripotent stem cell derived, clinical-stage neural cell therapy program, (hNSC-01), which we call HUNT1, for the treatment of Huntington’s Disease (HD). At the closing of the NeuroAirmid acquisition, Lineage (i) paid $2.4 million in cash to the Sellers, (ii) issued an aggregate of 2.2 million Lineage common shares to the Sellers (which was calculated by dividing $2.1 million by the volume-weighted average price of Lineage common shares over the 20 trading days ending two days before the closing), (iii) paid $0.2 million into an expense fund for use by the Sellers’ representative, and (iv) paid an aggregate of $1.7 million to satisfy NeuroAirmid’s obligations to third parties. Lineage also agreed to pay up to the following amounts to the Sellers and in respect of obligations of NeuroAirmid at the closing: (a) up to $5.4 million on the first anniversary of the closing; (b) up to $48.0 million in the aggregate contingent upon achievement of specified clinical development and regulatory milestones relating to the HUNT1 program Open the document at this passage
Nov 12
Current report 8-K
NeuroAirmid acquisition adds Phase 1b/2a Huntington’s Disease therapy

Lineage acquired NeuroAirmid on November 12, 2026, adding HUNT1, a Phase 1b/2a Huntington’s Disease cell therapy. Closing consideration included $2.4 million in cash, 2.2 million common shares, and up to $48.0 million in clinical and regulatory milestones.

Entered into a material agreement, Completed an acquisition or sale of assets, Financial results, Unregistered sale of equity, Regulation FD disclosure Read from the first part of this long document
4 source passages
On November 12, 2026, Lineage Cell Therapeutics, Inc. (“Lineage” or the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with all of the stockholders (the “Sellers”) of NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), and Leslie Thompson, as the representative of the Sellers, pursuant to which Lineage acquired from the Sellers all of the outstanding shares of NeuroAirmid common stock (the “Acquisition”). HUNT1 is currently being evaluated in a Phase 1b/2a clinical study known as the REGEN4HD clinical study (ClinicalTrials.gov ID NCT07451613). At the closing of the Acquisition, Lineage (i) paid $2.4 million in cash to the Sellers, (ii) issued an aggregate of 2.2 million Lineage common shares to the Sellers Lineage also agreed to pay up to the following amounts to the Sellers and in respect of obligations of NeuroAirmid at the closing: (a) up to $5.4 million on the first anniversary of the closing; (b) up to $48.0 million in the aggregate contingent upon achievement of specified clinical development and regulatory milestones relating to the HUNT1 program Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$10.84M
Trailing 12 months
Net income (TTM)
$1.75M
Trailing 12 months
Revenue growth YoY
-61.0%
Year over year
Operating margin
-280.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$45.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.2%
Year over year · more shares
Price change (1Y)
-53.8%
Trailing year
Short interest
9.6%
Latest settlement · 19.3 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Lineage reported Q2 net income of $1.5M driven by a non-cash $9.4M gain from warrant liability remeasurement as share price declined, while advancing wholly-owned pipeline assets COR1 into in vivo animal testing and ILT1 to multi-liter scale, and expanding the OpRegen GAlette study to 17 sites. Cash runway was extended one quarter to Q3 2028 at $50.8M.

Bullish
  • + Cash runway extended one quarter to Q3 2028 at $50.8M
  • + COR1 program advanced into in vivo animal testing with initial preclinical data expected in 2026
  • + ILT1 manufacturing initiative scaled from 0.5L to multi-liter scale
  • + OpRegen GAlette study expanded from 6 to 17 clinical sites
  • + Positive 3-year OpRegen Phase 1/2a data featuring sustained BCVA gains was showcased at Retinal Therapeutics Innovation Summit 2026
Bearish
  • − Total Q2 revenues declined $1.7M year-over-year to $1.1M due to lower Roche collaboration revenue and prior-year VAC termination
  • − Q2 R&D expenses increased $1.7M year-over-year to $4.8M driven by preclinical programs
  • − Diluted EPS was a loss of $0.03 despite reported basic net income of $0.01 per share, reflecting dilution from warrants

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −21%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −36%
trailing
YTD return −54%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$871.0K over 90 days · 0% sells
Short interest Falling
9.63% of shares out · ▼ -6.1% MoM · 19.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
144 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Strong
Revenue growth +53%
Y/Y
Gross margin 57%
contracting
EPS growth −211%
Y/Y
Free cash flow $-19.4M
Balance sheet $40.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −61%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
On the first anniversary of the transaction closing
Final installment of the upfront payment (cash) $2.6M
Cash payment to CERN $356,000
per year
Clinical costs for the program up to $2M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+9% holders QoQ · +29 funds added
Insider flow Accumulating
Net +$871.0K over 90 days · 0% sells
Short interest Falling
9.63% of shares out · ▼ -6.1% MoM · 19.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
144 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $2
vs 200-day avg -39% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
clinical award $12M third quarter 2026 —
clinical sites 17 third quarter 2026 —
Cohort 4 patients 12 third quarter 2026 —
patients dosed with HUNT1 6 third quarter 2026 —
payment to NeuroAirmid investors $4.7M Upon closing of the transaction —
translational funding $16M third quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LCTX
Lineage Cell Therapeutics, Inc.
this stock
$195.26M -53.8% +53.2% — 9.6%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
144
% held
46.3%
Net QoQ
+426.4K sh
Top holder
BROADWOOD CAPITAL INC
Held Float
View
Held by Funds
Fund positions
77
View
Short & Settlement
Short Interest Falling
Shares short
24.3M
Days to cover
19.3d
Change
-1.6M sh
View
Short Volume
Short vol %
43%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.3K
Value
$4.4K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
67.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$871.0K
Buyers / Sellers
5 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$14.6M
Net income (FY)
$-63.5M
EPS diluted
$-0.28
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
14

Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones.

View
Proposed Sales
Value
$96.0K
Shares
60.0K
Filed
Sep 24, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Lineage Cell Therapeutics Reports…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
LCTX -15.6% -22.8% -36.2% -22.8% -53.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -7.0% -13.6% -27.0% -14.1% -54.9%
Key facts CIK 876343 CUSIP 53566P109 13F (30d) 146 filings 122 filers Visit website Investor relations